Tectonic Therapeutics Gets Strong Buy Upgrade: Two Potential Blockbusters in Focus
Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.